Developments with investigational Janus kinase inhibitors for rheumatoid arthritis

Expert Opinion on Investigational Drugs

Volumn 25, Issue 12, 2016, Pages 1355-1359

  Semerano, Luca ^a,b,c   Decker, Patrice ^a,b   Clavel, Gaëlle ^b,d   Boissier, Marie Christophe ^a,b,c  

^a MALIBUL and INSERM UMR1125   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

ABT 494; baricitinib; decernotinib; filgotinib; janus kinases; peficitinib; Rheumatoid arthritis; tofacitinib

Indexed keywords

BARICITINIB; FILGOTINIB; JANUS KINASE 1; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3 INHIBITOR; JANUS KINASE INHIBITOR; UPADACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE; PROTEIN KINASE INHIBITOR;

CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; EDITORIAL; ENZYME INHIBITION; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; ENZYMOLOGY; PATHOPHYSIOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; HUMANS; JANUS KINASES; PROTEIN KINASE INHIBITORS;

EID: 84994071441     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1249565     Document Type: Editorial

References (26)

1. Semerano L, Minichiello E, Bessis N, et al. Novel immunotherapeutic avenues for rheumatoid arthritis. Trends Mol Med. 2016;22:214–229.
2. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.• Comprehensive review discussing cytokine signalling via JAK pathways.
3. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.• First clinical trial showing that a JAK inhibitor (tofacitinib) is effective and numerically similar to a TNF-inhibitor (adalimumab) as add-on therapy in MTX-insufficent responders.
4. Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis:a randomized trial. Ann Intern Med. 2013;159:253–261.
5. Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate:twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.
6. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
7. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors:a randomised phase 3 trial. Lancet. 2013;381:451–460.
8. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.•• Phase 3 clinical trial showing the efficacy of tofacitinib at 5mg twice daily dose at preventing radiological progression in RA.
9. Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2924–2937.
10. Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor:analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75:831–841.•• Pooled analysis of the risk of malignancy during tofacitinib development program.
11. Semerano L, Thiolat A, Minichiello E, et al. Targeting IL-6 for the treatment of rheumatoid arthritis:Phase II investigational drugs. Expert Opin Investig Drugs. 2014;23:979–999.
12. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis:preclinical characterization of INCB028050. J Immunol. 2010;184:5298–5307.
13. Fleischmann R, Takeuchi T, Schlichting DE, et al. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs):phase 3 trial results [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10):1045.• Abstract from a phase 3 clinical trial showing the superiority of baricitinib vs. methotrexate monotherapy in early csDMARDs naïve RA.
14. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243–1252.
15. Taylor PC, Keystone EC, Van Der Heijde D, et al. Baricitinib versus placebo or adalimumab in patients with active Rheumatoid Arthritis (RA) and an inadequate response to background methotrexate therapy:results of a Phase 3 study [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10):2L.• Abstract from a phase 3 clinical trial showing the superiority of baricitinib vs. adalimumab as add-on therapy in MTX-insufficient responders.
16. Genovese MC, Greenwald M, Codding C, et al. A Phase 2b, randomized, double-blind, parallel-group, placebo-controlled, dose-finding, multi-center study to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects not on concomitant methotrexate [abstract]. Arthritis Rheumatol. 2014;66(Suppl 10):2826.
17. Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan:a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75:1057–1064.
18. Galien, R., Brys R, Van der Aa A, et al. Absence of effects of filgotinib on erythrocytes, CD8+ and NK cells in rheumatoid arthritis patients brings further evidence for the JAK1 selectivity of filgotinib [abstract]. Arthritis Rheumatol. 2015;67(Suppl10):2781.
19. Westhovens R, Alten R, Pavlova D, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis:results from a Phase 2B dose ranging study [abstract]. Arthritis Rheumatol. 2015;67(Suppl10):1048.
20. Kavanaugh A, Ponce L, Cseuz R, et al. Filgotinib (GLPG0634), an Oral JAK1 selective inhibitor is effective as monotherapy in patients with active rheumatoid arthritis:results from a Phase 2B dose ranging study [abstract]. Arthritis Rheumatol. 2015;67(Suppl10):1049.
21. Kremer JM, Keystone EC, Emery P, et al. Safety and Efficacy of ABT-494, a novel selective JAK1 inhibitor, in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy [abstract]. Arthritis Rheumatol. 2015;67:Suppl10:14L.
22. Mahajan S, Hogan JK, Shlyakhter D, et al. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015;353:405–414.
23. Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol. 2015;67:334–343.
24. Genovese MC, Van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68:46–55.• Phase 2b clinical trial showing that a JAK3-selective inhibitor is effective as add-on therapy in MTX-insufficent responders in RA.
25. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update. Ann Rheum Dis. 2014;73:492–509.
26. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.